ITRACONAZOLE ( DrugBank: Itraconazole )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
3脊髄性筋萎縮症1
46悪性関節リウマチ1
65原発性免疫不全症候群1
96クローン病1
227オスラー病1
299嚢胞性線維症5

3. 脊髄性筋萎縮症


臨床試験数 : 237 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02633709
(ClinicalTrials.gov)
January 7, 201615/12/2015A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy VolunteersA Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy SubjectsSpinal Muscular AtrophyDrug: Itraconazole;Other: Placebo;Drug: RisdiplamHoffmann-La RocheNULLCompleted18 Years45 YearsMale33Phase 1Netherlands

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05404724
(ClinicalTrials.gov)
June 25, 202231/5/2022Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy SubjectsStudy on the Pharmacokinetic Effects of Single-centered, Open, Single-arm, Fixed-sequence Itraconazole on SHR0302 Tablets in Healthy SubjectsRheumatoid ArthritisDrug: itraconazole? SHR0302 tabletsJiangsu HengRui Medicine Co., Ltd.NULLCompleted18 Years45 YearsMale14Phase 1China

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00001280
(ClinicalTrials.gov)
January 19913/11/1999Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous DiseaseItraconazole for the Prevention of Fungal Infections in Chronic Granulomatous DiseaseMycosesDrug: itraconazoleNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompletedN/AN/ABoth100Phase 2United States

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05049525
(ClinicalTrials.gov)
February 22, 202225/8/2021Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's DiseaseEvaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Not Responding Adequately to Current TherapyCrohn's Disease;Inflammatory Bowel DiseasesDrug: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.;Drug: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.Montreal Heart InstituteNULLRecruiting18 Years65 YearsAll68Phase 2Canada

227. オスラー病


臨床試験数 : 56 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003272-31-NL
(EUCTR)
18/05/201811/01/2018Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasiaEfficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patients Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease
MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850
MedDRA version: 20.0;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Sporanox
Product Name: Itraconazole
St. Antonius ZiekenhuisNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2Netherlands

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01576315
(ClinicalTrials.gov)
June 201429/3/2012ATCF (Azole Therapy in Cystic Fibrosis)Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus.Cystic Fibrosis;Aspergillus InfectionsDrug: Itraconazole/voriconazoleRennes University HospitalNULLCompleted12 YearsN/ABoth11Phase 2France;United Kingdom
2NCT01768663
(ClinicalTrials.gov)
January 201311/1/2013A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult SubjectsA Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult SubjectsCystic FibrosisDrug: Lumacaftor;Drug: Ivacaftor;Drug: Ciprofloxacin;Drug: Itraconazole;Drug: RifampinVertex Pharmaceuticals IncorporatedNULLCompleted18 Years55 YearsBoth80Phase 1United States
3EUCTR2011-005799-41-GB
(EUCTR)
04/10/201221/08/2012Azole Therapy in Cystic Fibrosis (ATCF)Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and ofvoriconazole in patients with cystic fibrosis and presenting withpersistent positive sputums for Aspergillus - Azole Therapy in Cystic Fibrosis (ATCF) Cystic fibrosis
MedDRA version: 14.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.1;Level: HLT;Classification code 10003486;Term: Aspergillus infections;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: SPORANOX
Product Name: Sporanox 10 mg/ml Oral Solution
INN or Proposed INN: ITRACONAZOLE
Other descriptive name: SPORANOX
Trade Name: V-Fend
Product Name: VFEND 40 mg/ml powder for oral suspension
INN or Proposed INN: voriconazole
Other descriptive name: Vfend
CHU de Rennes (Rennes University Hospital Centre)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150United Kingdom
4NCT00787917
(ClinicalTrials.gov)
November 20087/11/2008An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA)Cystic Fibrosis;Allergic Bronchopulmonary AspergillosisDrug: Omalizumab;Drug: Placebo;Drug: ItraconazoleNovartis PharmaceuticalsNULLTerminated12 YearsN/AAll14Phase 4Belgium;Germany;Italy;Netherlands;United Kingdom
5NCT00528190
(ClinicalTrials.gov)
October 200710/9/2007Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic FibrosisTreatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled TrialCystic FibrosisDrug: ItraconazoleOttawa Hospital Research InstituteThe Hospital for Sick Children;Canadian Cystic Fibrosis Foundation;The Physicians' Services Incorporated FoundationCompleted6 YearsN/AAll35Phase 4Canada